MedInCell Stock Rebounds by 2.29% Despite a 15.71% Decline Over Three Months
MedInCell's stock has risen by 2.29% at midday this Tuesday, March 10, trading at 22.32 euros after closing at 21.82 euros the previous day. This technical rebound occurs as the CAC 40 gains 2.16% during the session and all European markets show positive dynamics. However, the Montpellier-based biotech company is still down by 3.54% over seven days and 15.71% over three months.
MedInCell's stock price is currently below its main moving averages, indicating a still fragile underlying trend. The 50-day moving average is at 24.78 euros, significantly above the current price, while the 200-day moving average, at 23.03 euros, now acts as an intermediate resistance. The RSI, at 36, indicates a relative oversold zone: this level, often associated with a potential short-term rebound, coincides with the surge observed this Tuesday. The support identified at 21.32 euros has played its role during recent lows, providing a technical floor that allowed the stock to stabilize before today's rebound. The major resistance is at 27.76 euros, more than 24% above the current price, illustrating the extent of the recovery needed to reverse the correction of recent months. The monthly volatility, measured at 14.98%, remains moderate, and the beta of 0.27 confirms the stock's low correlation with the overall market.
Annual Performance and Upcoming Financial Milestones
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Despite the significant decline over the past quarter, MedInCell's stock has shown remarkable performance over a year, with a gain of 59.89%. This trajectory reflects the advances of the company specialized in long-duration injection technologies, whose development pipeline has supported valuation over the past twelve months. Investors will soon turn their attention to the publication of the annual results for the fiscal year 2025-2026, scheduled for June 16, 2026. This date will be a crucial appointment to assess the financial trajectory of the biotech, particularly the evolution of its revenue related to licensing agreements and the progress of its clinical programs. The general meeting is set for September 10, 2026, followed by the semi-annual results of the 2026-2027 fiscal year on December 8, 2026. Moreover, the market context remains marked by high tension, with the VIX standing at 29.49 points at its last quote on March 6, sharply up from the previous day. However, Asian markets closed significantly higher this Tuesday: the Nikkei 225 ended up 2.88% and the Hang Seng 2.17%, contributing to the positive momentum observed in European markets during this session.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Context
Period
Period: 9M 2025
Guidance from the release
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.